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Abstract
Background: Coeliac disease affects approximately 1% of the population and is increasingly diagnosed in the
United Kingdom. A nationwide consultation in England has recommend that state-funded provisions for gluten-free
(GF) food should be restricted to bread and mixes but not banned, yet financial strain has prompted regions of
England to begin partially or fully ceasing access to these provisions. The impact of these policy changes on
different stakeholders remains unclear.
Methods: Prescription data were collected for general practice services across England (n = 7176) to explore
changes in National Health Service (NHS) expenditure on GF foods over time (2012–2017). The effects of sex, age,
deprivation and rurality on GF product expenditure were estimated using a multi-level gamma regression model.
Spending rate within NHS regions that had introduced a ‘complete ban’ or a ‘complete ban with age-related
exceptions’ was compared to spending in the same time periods amongst NHS regions which continued to fund
prescriptions for GF products.
Results: Annual expenditure on GF products in 2012 (before bans were introduced in any area) was £25.1 million.
Higher levels of GF product expenditure were found in general practices in areas with lower levels of deprivation,
higher levels of rurality and higher proportions of patients aged under 18 and over 75. Expenditure on GF food
within localities that introduced a ‘complete ban’ or a ‘complete ban with age-related exceptions’ were reduced by
approximately 80% within the 3 months following policy changes. If all regions had introduced a ‘complete ban’
policy in 2014, the NHS in England would have made an annual cost-saving of £21.1 million (equivalent to 0.24% of
the total primary care medicines expenditure), assuming no negative sequelae.
Conclusions: The introduction of more restrictive GF prescribing policies has been associated with ‘quick wins’ for
NHS regions under extreme financial pressure. However, these initial savings will be largely negated if GF product
policies revert to recently published national recommendations. Better evidence of the long-term impact of
restricting GF prescribing on patient health, expenses and use of NHS services is needed to inform policy.
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Background
Healthcare services across Europe are under increasing fi-
nancial pressure [1]. In 2015/2016 England’s state-funded
National Health Service (NHS) deficit reached £1.85 bil-
lion, the largest deficit in NHS history [2]. Despite a sub-
sequent reduction in the deficit in 2016/2017 [3], there is
ongoing pressure to achieve the NHS Five Year Forward
View’s target of finding savings of £22 billion by 2020
[4]. These financial difficulties prompt healthcare
decision-makers to reconsider what the NHS can af-
ford to provide. A widely noted reaction to this pres-
sure has been the increasing prioritisation of
cost-saving in the management of medicines, and sub-
sequent disinvestment in prescribed items deemed to
be of ‘low clinical value’ such as travel vaccines and
homeopathy [5]. Another highly debated example is the
prescription of gluten-free (GF) foods for people with glu-
ten enteropathy, also known as coeliac disease (CD) [6].
CD is an autoimmune disease characterised by gastro-
intestinal symptoms following the ingestion of grains
containing gluten (wheat, barley and rye) [7, 8], which
affects approximately 1% of the population of Europe
[9]. There was a four-fold increase in the incidence rate
of CD recorded in the UK between 1990 and 2011,
which was largely attributed to increased availability of
routine diagnostic tests and greater awareness among
clinicians and patients [10]. Like many autoimmune dis-
eases [11], CD is diagnosed at a higher rate among
women [10]. There is also evidence that the diagnosis of
CD is higher within populations with lower levels of so-
cioeconomic deprivation [12].
Unlike other autoimmune diseases, the only clinically
effective treatment for CD is lifelong adherence to a GF
diet [13], which is likely to be more financially burden-
some than purchasing conventional products that con-
tain gluten [14, 15]. Healthcare systems across the globe
have approached this challenge in a variety of different
ways. For example, people with CD in Canada are eli-
gible for tax reductions to compensate for the additional
costs of purchasing GF foods, while in Italy they are pro-
vided with a monthly cash allowance [16]. In the UK,
the NHS has provided GF foods on prescription since
the 1960s [17]. NHS prescriptions are available for a
range of staple goods such as bread and pasta, along
with sweet products such as cakes and biscuits [18]. A
study into CD prevalence in the UK found that 80% of
patients diagnosed with CD were in receipt of at least
one GF prescription product through the NHS [10].
In February 2018, NHS England released the results of
a nation-wide consultation and announced that prescrip-
tions for GF foods should be restricted to bread and
mixes (which can be used to make bread products such
as rolls and loaves) [19]. The policy review was
prompted by the increased accessibility of GF foods, in
comparison to when GF food prescriptions were first in-
troduced [20]. However, prior to this policy decision, an
increasing number of NHS England’s Clinical Commis-
sioning Groups (CCGs) had already begun to fully or
partially cease funding for prescriptions of GF products
in some localities [21]. In sum, the prescription of clinic-
ally effective and widely available food products high-
lights a grey area concerning what should (and what
should not) be considered ‘medicine’.
The overarching aim of the study was to investigate the
impact of potential policy changes on different stake-
holders (patient groups and CCGs), by exploring three
distinct objectives. First, we described changes in expend-
iture on GF products across all CCGs in England between
2012 and 2017. Next, we estimated GF food prescribing
expenditure (for 2014) by general practitioner (GP) prac-
tice demographics, rurality and deprivation to identify
groups of patients likely to be affected most by reduced
prescribing of GF products. Finally, in a separate analysis,
we compared the cost-savings made by CCGs which have
switched to a ‘complete ban’ or a ‘complete ban with
age-related exceptions’ with CCGs that have continued to
provide GF product prescriptions.
Methods
Datasets
Prescribing data
Prescriptions for GF products were accessed through
‘ OpenPrescribing.net, EBM DataLab, University of Oxford,
2017’, a resource that organises and presents the raw anon-
ymised prescription data released by NHS Digital each
month. These data are based on all NHS prescriptions dis-
pensed in primary care pharmacies in England. For this
study, OpenPrescribing provided us with a custom extract
of the data containing the ‘actual cost’ of spending on GF
products for all GP practices within England (grouped by
CCG). NHS Digital defines ‘actual cost’ as the cost to the
NHS, rather than the basic price of a drug or product (Net
Ingredient Cost). The extract contained data on spending
by each GP practice for each month from January 2012
through to June 2017. GF products were classified into
three categories as bread products, staple products (e.g.
flour and pasta) and other products (e.g. snacks and bis-
cuits). A complete list of the products in each category is
presented seperately (Additional file 1).
GP practice characteristics
We used data from NHS Digital from 2014 to calculate
the percentage of registered patients who were female
for each GP practice [22]. We used Public Health
England’s National General Practice Profiles (2014) to
characterise GP practices in terms of, percentage of reg-
istered patients under 18 years of age, percentage of reg-
istered patients 75 years of age or older, population size
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(list size), Indices of Multiple Deprivation (IMD) score
from 2015, and parent CCG [23]. By linking each GP
practice postcode to a Lower Layer Super Output Area
we were able to classify each GP practice by its level of
rurality [24]. Specific Lower Layer Super Output Area
rurality classifications were collated into broader cat-
egories as follows: Urban Conurbation (A1 and B1), Cit-
ies and Towns (C1 and C2), and Rural (D1, D2, E1 and
E2). Finally, a spending rate was calculated for each GP
practice as the total spend on GF prescriptions in 2014
per 1000 registered patients. We selected this time
period as it was the year before most NHS CCGs began
restricting their GF food policies. Of the 7596 practices
in the 2014 GP prescribing data, 7176 (94%) had
complete data once all datasets were linked on GP prac-
tice code. One further practice was excluded because
more than 80% of its patients were aged above 75.
CCG policies
Data on CCG policies for GF prescribing were extracted
from the Coeliac UK website [21]. After contacting all 207
CCGs, Coeliac UK reviewed policies for GF provisions as
part of their ‘Prescriptions Campaign’. This work resulted
in an interactive web-based map containing CCG policies
across England. Coeliac UK groups CCGs into four policy
types, as (1) partial or complete withdrawal of prescrip-
tions; (2) following national prescribing guidelines; (3)
restricting products and/or units; and (4) policy or GF pre-
scribing under review. Within this study these policy types
were re-categorised into (1) complete ban on prescriptions,
(2) complete ban on prescriptions (with age-related excep-
tions), (3) no ban on prescriptions, (4) partial restrictions
on products and/or units, and (5) policy under review. The
rationale for re-classifying the policies, particularly ‘(1) par-
tial or complete withdrawal of prescriptions’ was to recog-
nise the meaningful difference between a restriction and a
complete withdrawal of provisions. Verification of Coeliac
UK’s policy data against the information available on CCG
websites was conducted for a small, random selection of
CCGs (n = 21, 10%). For each of these CCGs, Coeliac UK’s
data accurately reflected the policy arrangements stated in
official statements on CCG websites.
The mapping between these policies is presented sep-
arately (Additional file 2). All policy data were extracted
by the research team (on 05/09/2017) and stored in a
spreadsheet. A summary table of the frequency of the
five policy types is presented in Table 1. The highest
number of CCGs followed a ‘partially restricted’ policy,
limiting the number of units and products available for
prescription (70/207, 34%).
Over one-quarter of CCGs had introduced a
‘complete ban’ or ‘complete ban with age-related excep-
tions’ (58/207, 28%). Due to the variability in policy de-
tails among CCGs with partial restrictions, and
availability of data on CCGs with policies under review,
this study focused on CCGs with no ban, a complete
ban, or a complete ban (with age-related exceptions).
Five bans were introduced in 2015 (complete bans = 4,
complete ban with age-related exceptions = 1), 22 in
2016 (complete bans = 17, complete ban with
age-related exceptions = 5), and 28 were introduced in
the first two-quarters of 2017 (complete bans = 16,
Complete ban with age-related exceptions = 12).
Statistical analysis
Total spending for each quarter was calculated across all
CCGs (N = 207) in England between 2012 (Quarter 1 –
January, February and March) and 2017 (Quarter 2 –
April, May and June). Total spending was split into the
three main product categories (bread products, staple
products and other products).
To estimate GF prescribing expenditure by GP prac-
tice demographics, rurality and deprivation, GP practices
with complete data (for 2014) were entered into a
multi-level gamma regression, using the ‘meglm’ com-
mand in Stata (version 14.2) with a gamma distribution
and log link function. We estimated how spending rate
varied with the following predictors: percentage of
women, percentage of population aged under 18, per-
centage of population aged 75+, IMD 2015 (classified
into quintiles, where 1 = least deprived), and rural/urban
classification. GP practices were clustered by their par-
ent CCG in the model.
To be eligible for inclusion in the examination of pol-
icy impacts on spending rates we required CCGs to have
GF spending data for at least 3 months following policy
changes. Given that the latest available data were for
June 2017, CCGs were eligible if they had switched to a
complete ban (n = 24) or partial ban with age-related ex-
ceptions (n = 8) prior to April 2017. The process under-
taken to match these CCGs to CCGs with a ‘no ban’
policy types was based on annual expenditure in 2014
and is outlined in separately (Additional file 3).
Table 1 Summary of Clinical Commissioning Group gluten-free
prescribing policies in 2017
Policy type Frequency (%)
Partial restrictions on products and/or unitsa 70 (34%)
No ban 61 (29%)
Complete ban 46 (22%)
Policy under review 18 (9%)
Complete ban (with age-related exceptions)b 12 (6%)
aPrescribing was limited to a lower number of monthly units or a restricted set
of products which was largely dependent on the individual Clinical
Commissioning Group
bGluten-free products still prescribed for children/adolescents under the age
of 18 or 19, and in some cases pregnant women
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Results
Spending on GF products in the past 5 years
Annual expenditure on GF products in 2012 (pre-policy
bans) was £25.1 million (Fig. 1). Throughout the study
period, ‘Bread products’ accounted for the largest propor-
tion (64–67%) of spending. Spending began to decline in
2015 when some CCGs introduced policies to restrict pre-
scribing. The lowest quarterly spending rate (£3.96 mil-
lion) was observed for 2017 (Quarter 2). This is equivalent
to a 39% reduction (quarterly saving of £2.58 million) in
overall expenditure since spending on GF products
peaked in the fourth quarter of 2014 (£6.54 million).
The impact of sex, age, rurality and deprivation on GF
spending
Regression results for GP practices with complete data
in 2014 (n = 7175) demonstrated deprivation had a
strong association with expenditure (Table 2). GP prac-
tices in the most deprived areas (IMD 5th quintile) had
the lowest spending rates on GF products (adjusted
point estimate 0.77, 95% confidence interval (CI) 0.72–
0.83). Incremental reductions in deprivation (lower quin-
tiles) were associated with incrementally higher spending
rates on GF products. GP practices in urban conurba-
tions had the lowest spending rates among the three
levels of rurality (adjusted point estimate 0.85, 95%
CI 0.78–0.93). GP practices with a higher percentage of
patients under 18 (adjusted point estimate 1.02, 95%
CI 1.02–1.03) and over 75 (adjusted point estimate 1.07,
95% CI 1.06–1.07) had higher spending on GF prescrip-
tions. Sex was not associated with spending on GF pre-
scriptions after adjusting for the remaining variables in
the model (adjusted point estimate 1.00, 95% CI 0.99–
1.01). As a sensitivity analysis, we examined whether
there was an interaction between rurality and
deprivation, yet the interaction term was not found to
be statistically significant (Additional file 4).
Trends in expenditure on GF products within CCGs with
alternative GF prescription policies
The average total monthly spending rates within CCGs
with a ‘complete ban’ policy, were compared to matched
CCGs that had ‘no ban’ on GF prescriptions, and to CCGs
with ‘complete ban with age-related exceptions’ (Fig. 2).
Further details on the spread of these data are presented
in Additional file 5. Over time, spending within CCGs
with no ban on GF prescribing remained unchanged. In
contrast, CCGs that introduced a complete ban saw an
average reduction in spending of approximately 80%
(equivalent to £9100–£9400 savings per CCG per month).
The effect of the policy change had an immediate impact
on spending and the reduction in spending levelled off
around the second month following policy change. A
comparable drop in spending was observed between
CCGs which introduced a complete ban and those which
had introduced a complete ban for adults only. Despite
matching CCGs on their annual expenditure in 2014, ex-
penditure was slightly lower in the ‘no ban’ CCGs in the
Fig. 1 Spending on gluten-free items (2012–2017) across all Clinical Commissioning Groups in England
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3 months leading up to the ban, which might reflect the
fact that policy reforms in some areas took some years to
implement. If all CCGs had introduced a complete ban on
GF prescriptions in 2014, and spending rates followed the
82.9% reduction observed in this study, the NHS in
England would have saved £21.1 million on GF products
that year. This figure is equivalent to 0.24% of the total ex-
penditure on medicines in primary care for 2014/2015
(£8.7 billion) [25].
Discussion
Main findings
We found that expenditure on GF products was reduced
by an average of approximately 80% within the 3 months
after CCGs introduced a ‘complete ban’ or ‘complete ban
with age-related exceptions’ on GF prescriptions. Spend-
ing on GF products peaked in the fourth quarter of 2014
(2014 Q4: £6.54 million) and has since fallen by approxi-
mately one-third (2017 Q2: £3.96 million). We estimate
that if all CCGs had introduced a ‘complete ban’ policy
for 2014 the NHS would have made an annual
cost-saving of £21.1 million. The policies are likely to
have the largest impact on spending among GP practices
in the least deprived areas, most rural locations and with
the highest proportion of patients over the age of 75.
Strengths and weaknesses of the study
To our knowledge, this is the first study to examine the
impact of GF product prescription policy changes on
cost-savings. As such, our work provides timely insight
into the financial implications of recent NHS England
GF prescription policy options. This study is
comprehensive and representative due to its use of pre-
scription data from all 207 CCGs in England. We explored
the cost-savings associated with introducing a ‘complete
ban’ or ‘complete ban with age-related exceptions’ com-
pared to CCGs with a ‘no ban’ policy. Differences in the
specific criteria used by CCGs with a ‘partial restriction on
products and/or units’ meant that they were not examined
in this analysis. Further, we did not have access to data on
the number of people with diagnosed CD in each GP
practice. Given our focus on prescription data, this work
presents one part of a larger story. For example, it is un-
clear what the impact of policy changes might be on the
frequency of consultations, medications or referral rates
for gastrointestinal symptoms.
Comparison with other studies
In line with evidence that CD is diagnosed at a higher rate
among more affluent patients [12], this study found that
spending on GF prescriptions was highest in GP practices
with the lowest levels of deprivation. One explanation for
this may be that symptom recognition and care seeking is
higher among people in higher socioeconomic positions
[26]. We also found that GF product expenditure was
higher within GP practices with higher proportions of
patients over the age of 75 and under the age of 18. In
England, patients in both of these age categories are ex-
empt from prescription charges, and therefore this obser-
vation is expected [27]. Finally, although CD is diagnosed
in more women than men [10], having a higher propor-
tion of female patients within GP practices was not associ-
ated with greater expenditure on GF products (when
controlling for rurality, age and deprivation).
Table 2 Modelling spending rate (in 2014), clustered by Clinical Commissioning Group, sex/age variables
Model predictors Unadjusted point estimate
(95% confidence interval)
Adjusteda point estimate
(95% confidence interval)
Sex
Change per % increase in female patients 1.03 (1.02–1.04) 1.00 (0.99–1.01)
Age
Change per % increase in patients ≤ 18 years 0.99 (0.99–1.00) 1.02 (1.02–1.03)
Change per % increase in patients ≥ 75 years 1.06 (1.05–1.07) 1.07 (1.06–1.07)
Level of rurality
Baseline: Rural 1 1
Towns and Cities 0.85 (0.81–0.90) 0.93 (0.89–0.98)
Urban Conurbation 0.73 (0.67–0.80) 0.85 (0.78–0.93)
Level of deprivation
Baseline: 1 – Least Deprived 1 1
2 0.88 (0.83–0.92) 0.93 (0.88–0.98)
3 0.80 (0.76–0.85) 0.88 (0.83–0.93)
4 0.71 (0.67–0.75) 0.80 (0.75–0.85)
5 – Most Deprived 0.67 (0.63–0.71) 0.77 (0.72–0.83)
aAdjusted for all other predictors in the model
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Implications for patients, clinicians and policymakers
The results of this study demonstrate that policy-driven re-
strictions on GF prescriptions have been a quick and ef-
fective strategy for CCGs to reduce their expenditure.
Given our findings, new national recommendations that
endorse the prescription of GF bread and mix products are
unlikely to yield meaningful cost savings for CCGs [19].
Additionally, the publication of national recommendations
3 years after CCGs began acting unilaterally is likely to cre-
ate further confusion amongst patients. These changes
may be particularly confusing within localities that previ-
ously ceased funding for GF products which may now de-
cide to reintroduce them to be in accordance with national
recommendations. The higher price paid by the NHS for
similar products that would cost less for patients to buy in
retail outlets remains a contentious topic [6]: however,
higher savings might be yielded if improvements were
made to the procurement processes currently in place.
While GF products may be increasingly available in re-
tail stores, they are not necessarily nutritionally equiva-
lent to the products prescribed currently through the
NHS. Prescribed products through specialist suppliers
such as Juvela [28] and Glutafin [29] are fortified with
calcium, iron, folic acid and B vitamins, nutrients that
CD patients are commonly deficient in due to malab-
sorption in the intestines [30]. In the UK, retail wheat
flour is typically fortified, yet this is not necessarily the
case with GF substitute products [31]. If policy changes
result in CD patients switching to retail suppliers for
their GF products, they may need to complement their
diet with additional nutritional supplements, which may
impose additional costs.
Despite technological advancements in the diagnosis
of CD, patients often wait many years (mean 5.8 years)
following their first GP consultation to receive a formal
diagnosis of CD [32], during which there is evidence of
Fig. 2 Average (mean) monthly spending within Clinical Commissioning Groups pre (3 months), during, and post (3 months) policy changes
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increased costs to the NHS [33]. If prescription policies
tighten, patients who have faced delayed diagnoses will
face the additional obstacle of no access to NHS pre-
scribed treatment.
Restricting GF prescribing may in fact be a false econ-
omy. If patients are unable to achieve a GF diet when
they do not have GF prescriptions [34], and this leads to
an increase in symptoms, then the policies will have a
negative effect on NHS resources and health outcomes
in the medium term. In addition, the restriction of GF
prescribing will have financial consequences for people
with CD. Although this study found that spending on
GF prescriptions has been highest amongst GP practices
in the least deprived areas, those less affluent patients
who do access GF prescriptions may be the most likely
to struggle with the added financial strain of adhering to
a GF diet in the absence of prescriptions [14]. To ad-
dress this knowledge gap, a qualitative examination into
the impact of these policy changes on patients would
provide useful insight into how the withdrawal of pre-
scriptions might influence compliance with a GF diet.
In the face of this mismatch between CCG policies and
national recommendations, a grey area concerning the ex-
tent to which ‘food’ products are considered ‘healthcare’ is
revealed. While the link between food and health is widely
noted [35–37], including food items such as GF bread
alongside pharmaceutical products on the national formu-
lary is, and will continue to be, controversial. This is par-
ticularly so given that prescription rates are highest
among GPs in more affluent areas, suggesting that GF
product prescriptions may not be reducing health inequal-
ities. In the longer term, the solution in England might be
for greater cooperation between the government, food
manufacturers and the retail industry to make GF prod-
ucts more affordable and widely available.
Future research
Despite many CCGs already opting to limit the prescrip-
tion of GF products [21], our understanding of the wider
impact of these policy changes remains incomplete. This
study explored the short-term financial consequence of
policy restrictions, but there is a need to also conduct
medium- and longer-term analyses to explore the resource
implications of these policy changes in terms of GP con-
sultations, hospital admissions and other forms of health-
care utilisation. Similarly, the impact of policy changes on
health outcomes could be highlighted by investigating in-
creases in the use of vitamin and mineral supplements,
and gastrointestinal drugs such as anti-diarrhoeals to
combat gluten-induced symptoms. Several studies have
indicated that GF foods can cost up to four-times as much
as gluten-containing alternatives [14, 15]; therefore, there
is a need to investigate the financial burden that more re-
strictive GF food policies shift onto patients.
Interestingly, NHS regions (CCGs) that implemented a
complete ban policy did not see a full reduction in ex-
penditure on GF products. Within the 3-month period
studied, spending within these CCGs decreased by ap-
proximately 80%, yet this also reveals that GF products
were still being prescribed and supplied while they were
banned. All of the CCGs (apart from one CCG at 2
months post-policy change) reported that expenditure
on GF products had not been completely reduced. One
explanation for this finding is that there may have been
slow or, in some cases, incomplete implementation of
policies within CCGs. Further exploration is needed into
the personal perspectives of GPs [38], and the excep-
tional circumstances that might be used as rationale for
prescribing banned products. As in other clinical set-
tings, there is a need to further explore the interplay be-
tween policy-level decision-making and prescribing
decisions made at the patient level [39].
Conclusions
The introduction of more restrictive GF prescribing pol-
icies has been associated with ‘quick wins’ for CCGs
under extreme financial pressure. However, these initial
savings will be largely negated if CCGs revert to recently
published national recommendations. Better evidence of
the long-term impact of restricting GF prescribing on
patient health, expenses and use of NHS services is
needed to inform policy.
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